Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Merck KGaA/Pfizer's 90 day exclusivity period in effect now

<< Previous

Bullboard Posts

Next >>

Comment by CarbonWarrioron Nov 23, 2022 11:36am

190 Views

Post# 35122111

RE:RE:RE:RE:RE:RE:Merck KGaA/Pfizer's 90 day exclusivity period in effect now

okay thanks for the info.
I still think that ONCY needs to do a press release for the 90 days period as it is material event.

They can't just say nothing and relase the data at ASCO in June.

Not sure were you got the June 2022 enrollement completion date.

Anyway, Share Price is not going down.

The only reason why people would sell are margin calls and tax losses.
Both reasons (pressure) are subsiding to nothing by year end.

Then the positive force of speculation comes in. The bet is that the outcome will be positive... The majority

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing